ALK and lung adenocarcinoma: In conclusion, our preliminary study demonstrated that radiomics signature derived from pretreatment CT can serve as a non-invasive biomarker for predicting BM in patients with stage III/IV ALK-positive lung adenocarcinoma, backed by an independent external test dataset.